INSYTE marks the first FDA-approved clinical trial of an intravascular optical imaging system designed specifically for the neurovasculature. The Spryte n OCT Imaging System uses high-resolution ...
Medtronic has raised its fiscal year 2026 (FY26) profit outlook to between $5.62 and $5.66 per share after the company achieved its strongest cardiovascular portfolio revenue growth in over a decade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback